AI Dermatology Imaging Global Market Report 2026

The artificial intelligence (AI) dermatology imaging market size has grown exponentially in recent years. It will grow from $1.12 billion in 2025 to $1.36 billion in 2026 at a compound annual growth rate (CAGR) of 20.7%. The growth in the historic period can be attributed to growing prevalence of skin disorders, increasing demand for accurate dermatology diagnosis, adoption of dermatoscopic imaging and clinical imaging, expansion of dermatology clinics and hospital networks, rising interest in telehealth platforms.

The artificial intelligence (AI) dermatology imaging market size is expected to see exponential growth in the next few years. It will grow to $2.9 billion in 2030 at a compound annual growth rate (CAGR) of 21%. The growth in the forecast period can be attributed to growing integration of ai-enabled analytics, increasing adoption of cloud-based deployment models, rising demand for automated disease screening and triage, expansion of research applications in dermatology imaging, growing focus on teledermatology and remote patient monitoring. Major trends in the forecast period include increasing adoption of cloud-based ai dermatology platforms, rising demand for multispectral and total body imaging solutions, growing integration of teledermatology services, expansion of ai-enabled treatment monitoring tools, rising focus on workflow automation and data management solutions.

The growing incidence of skin cancer is anticipated to fuel the expansion of the artificial intelligence (AI) dermatology imaging market in the coming years. Skin cancer is characterized by the uncontrolled growth of skin cells, frequently caused by exposure to UV radiation, resulting in malignant tumors such as melanoma and non-melanoma forms. The incidence of skin cancer is increasing due to heightened exposure to ultraviolet (UV) radiation from the sun and artificial tanning devices, which damage skin cells and elevate the risk of malignant developments. AI in dermatology imaging improves early detection and precise diagnosis of skin cancer by evaluating images of skin lesions through advanced algorithms, recognizing subtle patterns and irregularities that might be overlooked by the human eye, and facilitating quicker, more dependable clinical decisions for timely intervention. For example, in January 2026, according to the Skin Cancer Foundation, a US-based non-profit organization, the number of newly diagnosed melanoma cases is projected to increase by 10.6 percent. Therefore, the growing incidence of skin cancer is propelling the expansion of the artificial intelligence (AI) dermatology imaging market.

Leading companies operating in the artificial intelligence (AI) dermatology imaging market are focusing on developing innovative solutions such as AI-powered clinical imaging platforms to enhance diagnostic accuracy, streamline clinical trials, and provide objective, real-time skin assessments. AI-powered clinical imaging platforms are systems that combine advanced skin imaging with artificial intelligence algorithms to automatically capture, analyze, and score dermatological conditions, helping clinicians and researchers obtain faster, more objective, and standardized assessments compared with traditional manual evaluation. For example, in September 2025, QuantifiCare, a France-based medical imaging company, partnered with Legit.Health, a Spain-based AI healthcare company, to launch the first AI-powered dermatology imaging platform for clinical trials. The platform combines QuantifiCare’s 2D and 3D imaging systems with Legit.Health’s AI algorithms to provide immediate severity grading, real-time treatment response insights, and automated scoring of over 300 skin conditions. Key features include standardized imaging workflows, high reproducibility, reduced administrative workload, and enhanced reliability of clinical endpoints, making it a powerful tool for sponsors, CROs, and investigators seeking to accelerate dermatology research.

In December 2024, Omda AS, a Norway-based healthcare technology company, completed the acquisition of Dermicus AB for an undisclosed sum. Through this acquisition, Omda seeks to strengthen its technological expertise in AI-supported medical imaging and telemedicine, broaden its portfolio of digital health solutions, drive innovation in remote patient care, and reinforce its competitive standing within the Nordic healthcare technology market. Dermicus AB is a Sweden-based healthcare technology company specializing in AI-powered teledermatology, telewound care, and mobile imaging solutions for the remote diagnosis and management of skin conditions.

Major companies operating in the artificial intelligence (AI) dermatology imaging market are Google LLC, Microsoft Corporation, Perfect Corp., Canfield Scientific Inc., Proscia Inc., Behold.ai Inc., FotoFinder Systems GmbH, SmartSkin AI Inc., MetaOptima Technology Inc., QuantifiCare SA, SkinVision B.V., DermaSensor Inc., Skin Analytics Ltd, Haut.AI Inc., First Derm Inc., Enspectra Health Inc., SkinIO Inc., SciBase Holding AB, SkinIO LLC, GlamAR Group Inc., IQONIC.AI Inc., TeleSkin d.o.o., DermAI Inc.

North America was the largest region in the artificial intelligence (AI) dermatology imaging market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI) dermatology imaging market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) dermatology imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI) dermatology imaging market consists of revenues earned by entities by providing services such as skin lesion detection, mole mapping and monitoring, acne and psoriasis analysis, melanoma risk assessment, early skin cancer screening, automated image-based diagnosis, teledermatology support, and treatment response monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) dermatology imaging market also includes sales of AI-powered dermoscopy cameras, multispectral skin analysis systems, 3D skin surface scanners, edge-based dermatology diagnostic terminals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Artificial intelligence (AI) dermatology imaging is a technology that applies machine learning algorithms to examine skin images for diagnostic purposes. It identifies, classifies, and monitors various skin conditions by recognizing patterns, textures, and colors that indicate disease. AI-based analysis improves accuracy and efficiency in detecting dermatological abnormalities through automated image interpretation.

The essential components of artificial intelligence (AI) dermatology imaging include software, hardware, and services. Software refers to platforms that analyze dermatological images using AI algorithms for diagnostic and clinical decision support. Imaging modalities include dermatoscopic imaging, clinical imaging, reflectance confocal microscopy, optical coherence tomography, total body photography, and multispectral imaging. Deployment modes include cloud-based and on-premises solutions. Applications include disease diagnosis, treatment monitoring, screening and triage, teledermatology, and research, serving end users such as dermatology clinics, hospitals, telehealth platforms, primary care networks, and other sectors.

Tariffs on imported imaging devices, high-performance computing systems, and AI-enabled software platforms are impacting the AI dermatology imaging market by raising procurement and deployment costs. Segments such as dermatoscopic and multispectral imaging devices, as well as cloud-based software platforms, are most affected, particularly in regions like North America, Europe, and Asia-Pacific where imported technology is heavily relied upon. While tariffs increase costs, they also encourage local manufacturing, boost domestic software development, and drive innovation in cost-efficient, AI-enabled diagnostic solutions, creating long-term market growth opportunities.

The artificial intelligence (AI) dermatology imaging market research report is one of a series of new reports that provides artificial intelligence (AI) dermatology imaging market statistics, including artificial intelligence (AI) dermatology imaging industry global market size, regional shares, competitors with a artificial intelligence (AI) dermatology imaging market share, detailed artificial intelligence (AI) dermatology imaging market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) dermatology imaging industry. This artificial intelligence (AI) dermatology imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.